Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol 2020;12:549-557
Date
12/05/2020Pubmed ID
33273867Pubmed Central ID
PMC7705269DOI
10.2147/JEP.S259290Scopus ID
2-s2.0-85097884873 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT), occurring in up to 70% of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly morbid, with only 30% of patients surviving long term. Better therapies are urgently required for these patients. Here, we discuss recent advancements in the management of SR-aGVHD. We review the currently available therapies for SR-aGVHD including the results of the REACH1 and REACH2 trials, which provide the basis for the use of ruxolitinib for the treatment of SR-aGVHD. We additionally discuss newer agents under clinical investigation and will highlight the niche these agents may fill to further improve outcomes in aGVHD patient care.
Author List
Abedin S, Hamadani MAuthors
Sameem Abedin MD Associate Professor in the Medicine department at Medical College of WisconsinMehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin